LIMA, Peru, Dec. 2, 2024 /VB/ — MGI Tech Co., Ltd. (“MGI”), a company dedicated to advancing innovation in life science through the development of core tools and technologies, has announced a partnership with the Universidad de San Martín de Porres. This collaboration aims to enhance human genetics research by implementing next-generation genomic sequencing (NGS) technologies in the university’s Genetic and Molecular Biology Research Center laboratory. The utilization of these advanced technologies will facilitate the identification of genetic risk factors within the population, leading to the development of future public health treatments.
Carlos Carpio, Commercial Director for MGI Latin America, emphasizes that this partnership represents a significant milestone in genetic research in Peru and Andean countries. By enabling large-scale studies of human genomes, exomes, and metagenomics with enhanced speed and precision, this technological upgrade will revolutionize genetic research in the region. The automation of processes, from sample preparation to bioinformatic analysis, will not only reduce research times and costs but also democratize access to this technology, providing opportunities for specialized training in genomics and bioinformatics.
The laboratory at Universidad de San Martín de Porres is equipped with state-of-the-art technology, including the DNBSEQ-G400RS sequencer, the MGISP-100 automated library preparation system, and MGI’s MEGABOLT bioinformatics accelerator. This cutting-edge equipment will empower researchers to conduct advanced studies with unparalleled precision and efficiency.
Dr. Ricardo Fujita, Director of the Research Institute and investigator at the Genetic and Molecular Biology Research Center, highlights the importance of including Peruvians and Andean populations in medical and genomic studies. By addressing the lack of representation in global studies, researchers can identify genetic causes of various conditions and develop personalized treatments tailored to local needs.
Through this partnership, Dr. Fujita and his team will lead five ambitious research projects focusing on rare diseases, cancer, immunogenomics, pharmacogenomics, genetics of native populations, and metagenomics. These projects aim to contribute valuable data to open databases, advance genetic research, and promote personalized medicine in the region.
The incorporation of MGI Tech’s advanced technology will not only advance genetic research but also strengthen collaboration with hospitals and academic institutions to research prevalent diseases in the region. This initiative positions Universidad de San Martín de Porres as a leader in genomic research, driving the development of personalized medicine and enhancing understanding of human health.
MGI Tech Co., Ltd. is a leading company in life science dedicated to developing innovative tools and technologies. With a focus on research & development, manufacturing, and sales of instruments and reagents in the field of life science and biotechnology, MGI strives to drive innovation and impact globally. To learn more about MGI, please visit their website at https://en.mgi-tech.com/.
More Stories
DOH: Positivity and Proper Diet Are the Most Effective Medicine for a Healthy Heart
Auto parts manufacturers welcome assured funding for CARS program
Auto parts manufacturers welcome assured funding for CARS program